Drugs / SynGEM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02958540 | Oct 2016 → Jul 2017 | respiratory syncytial virus infectious disease | Mucosis BV | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SynGEM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958540 ↗ |
| Modality | Vaccine | “SynGEM is thus the first nonreplicating intranasal RSV subunit vaccine to induce persistent antibody responses in human volunteers.” PMID 30753101 ↗ Aug 2019 |
| Route | Intranasal | “receive placebo or SynGEM (low or high dose) intranasally by prime-boost administration.” PMID 30753101 ↗ Aug 2019 |